Periodontal Disease "Unrecognized Condition"DPOGDNASNCT02523326
Design of a Protocol for Obtaining Genomic DNA From Saliva
An observational study of Periodontal Disease "Unrecognized Condition", run by Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás at 1 site in Mexico.
Trial summary
Objective The aim of this study was to test a protocol for the extraction of high quality genomic DNA from saliva samples obtained with mouthwash and taken from patients with periodontal disease. Materials and methods Saliva samples were taken from 60 patients, then stored at room temperature. Read more about this study
- Who is it for?
- Ages 35 to 45 years
- Conditions the study is for
- Periodontal Disease "Unrecognized Condition"
- What is being tested?
- saliva samples obtained with mouthwash
- Type of treatment
- Medical device
- How many people
- 60 participants
- Where
- 1 siteMexico
- Study dates
- Feb 2015to Sep 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 45 years
- All sexes
- No healthy volunteers
- Adult
Study population: patients diagnosed with severe chronic periodontitis
Who may be able to join
- patients diagnosed with severe chronic periodontitis
- who signed the appropriate form allowing for the collection of saliva samples and the extraction of genomic DNA
Who cannot join
- NO diagnosed with severe chronic periodontitis
- NO signed the appropriate form allowing for the collection of saliva samples and the extraction of genomic DNA
Trial locations and contacts
1 site in 1 country.
Mexico1 site, 1 recruiting
- Recruiting
Angel Chavez Mendoza
México, D.f., 11340
Higinio Estrada Juárez, DOCTORATE, 55209900 ext. . 287, higinio.estrada@inper.mx
About this study
Official title: Design of a Protocol for Obtaining Genomic DNA From Saliva Using Mouthwash: Samples Taken From Patients With Periodontal Disease
Objective The aim of this study was to test a protocol for the extraction of high quality genomic DNA from saliva samples obtained with mouthwash and taken from patients with periodontal disease.
Materials and methods Saliva samples were taken from 60 patients, then stored at room temperature. DNA extraction was carried out at distinct post-sampling times (10, 20 and 30 days). Evaluation of genomic DNA was performed with spectrophotometry, electrophoresis, and PCR genotyping and sequencing.
Read the detailed description
Materials and methods 2.1. Patients The study was conducted with 60 patients diagnosed with severe chronic periodontitis in the Periodontic Clinic of the Interdisciplinary Health Sciences Center (Santo Tomás Unit), National Polytechnic Institute. The protocol of this study was approved by the Research and Bioethics Committee of the School of Medicine. National Polytechnic Institute. Informed consent was obtained from all participants included in the study, who signed the appropriate form allowing for the collection of saliva samples and the extraction of genomic DNA. Ethical norms for research on human beings, established by the Declaration of Helsinki (1975; updated most recently in 2008) were strictly followed. Each patient was instructed how to prepare for saliva sampling, which involved brushing their teeth at least 2 h previously and abstaining from eating or drinking anything.
2.2. Taking the sample In a tube of 50 ml were placed 10 ml mouthwash (Listerine Cool Mint, Johnson \& Johnson, 21.6% alcohol). Patients were instructed to rinse their mouth vigorously with this quantity of mouthwash during 30 s, then spit it into the tube. Once collected, the samples were stored at room temperature (20°C - 24°C). The 60 samples were divided into 3 groups (n=20), and the extraction of DNA was performed at distinct times: group A at 10 days, group B at 20 days and group C at 30 days.
2.3. DNA extraction To separate the mouthwash, the tube was centrifuged during 10 min at 10750x g. The supernatant was poured out and the cellular pellet washed with 1 ml of PBS, resuspended in the vortex for 30 s, and transferred to a new 2 ml tube. It was then centrifuged for 5 min at 2000x g, the supernatant poured out, and the pellet washed with 1.5 ml of PBS and resuspended in the vortex for 30 s. To this solution was added a 1 ml solution of lysis of nucleated cells (Wizard® Genomic DNA Purification Kit) before being shaken for 20 s, followed by incubation at 37 °C for 10 min. After adding 300 µl of protein precipitator solution (Wizard® Genomic DNA Purification Kit), the mixture was placed on ice for 5 min and then centrifuged at 15000x g for 3 min. The supernatant was put in a 1.5 ml tube containing 600 µL cold Isopropanol and homogenized gently, then centrifuged at 15000x for 3 min. The supernatant was poured out and 600 µL of 70% ethanol were added to a fresh preparation, which was centrifuged at 15000x g for 3 min. The supernatant was poured out and the tube was completely dried at room temperature. Finally, 100 µL rehydration solution (Wizard® Genomic DNA Purification Kit) was added and the mixture was incubated at 64 °C for 1 h before storing the samples at -20 °C to await further processing.
2.4. DNA evaluation Evaluation of the concentration and purity of DNA was determined by spectrophotometry with an ACT-GENE ASP-3700 spectrometer. The concentration of DNA was evaluated at 260 nm, while purity was estimated with the ratios of 260/203 and 260/280. The integrity of genomic DNA was assessed in a 0.8% agarose gel in 1% TBE (89 mM Tris Borate, 89 mM boric acid, 2 mM EDTA) by electrophoresis, and then the DNA was visualized with Gel-Red and read under UV light. DNA extracted from blood samples was used as the positive control.
2.5. PCR The PCR reaction was carried out in an Eppendorf Mastercycler® Personal apparatus with the HotStarTaq ® Master Mix Qiagen kit (No. de Cat 203445), following the manufacturer's instructions. To verify the quality and species (human) of the DNA extracted, primers were designed for the rs679620 polymorphism (forward 5´- ggg gCT TAA ggC ACA TgA gT-3; reverse 5´- ACT TCg ggA TgC CAg gAA Ag - 3´; Tm: 56°C, 40 cycles) that amplified a product of 485 bp. The final PCR product was evaluated with a 2% agarose gel. DNA extracted from blood samples was used as a positive control.
2.6. Sequencing To further verify the quality and species of the DNA obtained, the product resulting from PCR was sequenced with an Applied Biosystems 3130 sequencer and the BigDye® Terminator v3.1 Cycle Sequencing kit, following the manufacturer's instructions. Data were analyzed with Geneious version 7.1.3 software [23], using the NC_000011.10 sequence as the reference.
- Being tested
- saliva samples obtained with mouthwash
- Keywords
- Genomic DNA, chronic periodontitis, saliva, mouthwash, PCR, genotyping, sequencing
- Medical subject headings
- Chronic Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
saliva samples obtained with mouthwashDevice
saliva samples obtained with mouthwash
| Study group | Role | What they receive |
|---|---|---|
| Group A | Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group A at 10 days Receives: Device: saliva samples obtained with mouthwash | |
| Group B | Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group B at 20 days Receives: Device: saliva samples obtained with mouthwash | |
| Group C | Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group C at 30 days Receives: Device: saliva samples obtained with mouthwash |
What is being measured
The primary outcome is the main question the study is designed to answer.
DNA
high quality genomic DNA from saliva samples obtained with mouthwash.
Measured: 10 days [group A], 20 days [group B], 30 days [group C]
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2015 (estimated)
- Study startFeb 2015
- Primary completionAug 2015
- Study completionSep 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal Disease "Unrecognized Condition"Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ÁNGEL CHÁVEZ MENDOZA, Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás
- Investigators
- Beatriz Buentello Volante, Doctorate, Principal investigator, Instituto de Oftalmología "Conde de Valenciana".María Esther Ocharán Hernández, Doctorate, Principal investigator, Escuela Superior de Medicina, Instituto Politécnico NacionalClaudia Camelia Claudia Camelia Calzada Mendoza, Doctorate, Principal investigator, Escuela Superior de Medicina, Instituto Politécnico NacionalArturo Flores Pliego, Doctorate, Principal investigator, Instituto Nacional de PerinatologiaHéctor A. Baptista Gonzalez, Doctorate, Principal investigator, Instituto Nacional de PerinatologiaHiginio Estrada Juárez, Doctorate, Study director, Instituto Nacional de Perinatologia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02523326
- Sponsor's protocol ID
- CentroICSUT
- Acronym
- DPOGDNAS
- Status last verified
- Aug 2015
- First submitted
- 4 Aug 2015
- Last updated
- 14 Aug 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Design of a Protocol for Obtaining Genomic DNA From Saliva Using Mouthwash: Samples Taken From Patients With Periodontal Disease
- ClinicalTrials.gov ID
- NCT02523326
- Acronym / sponsor ID
- DPOGDNAS / CentroICSUT
- Keywords
- Genomic DNA, chronic periodontitis, saliva, mouthwash, PCR, genotyping, sequencing
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Centro Interdisciplinario de Ciencias de la Salud Unidad Santo TomásUniversity, hospital or other
- Study start
- Feb 2015
- Primary completion
- Aug 2015 (actual)
- Study completion
- Sep 2015 (estimated)
- First posted
- 14 Aug 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective The aim of this study was to test a protocol for the extraction of high quality genomic DNA from saliva samples obtained with mouthwash and taken from patients with periodontal disease.
Materials and methods Saliva samples were taken from 60 patients, then stored at room temperature. DNA extraction was carried out at distinct post-sampling times (10, 20 and 30 days). Evaluation of genomic DNA was performed with spectrophotometry, electrophoresis, and PCR genotyping and sequencing.
Detailed description
Materials and methods 2.1. Patients The study was conducted with 60 patients diagnosed with severe chronic periodontitis in the Periodontic Clinic of the Interdisciplinary Health Sciences Center (Santo Tomás Unit), National Polytechnic Institute. The protocol of this study was approved by the Research and Bioethics Committee of the School of Medicine. National Polytechnic Institute. Informed consent was obtained from all participants included in the study, who signed the appropriate form allowing for the collection of saliva samples and the extraction of genomic DNA. Ethical norms for research on human beings, established by the Declaration of Helsinki (1975; updated most recently in 2008) were strictly followed. Each patient was instructed how to prepare for saliva sampling, which involved brushing their teeth at least 2 h previously and abstaining from eating or drinking anything.
2.2. Taking the sample In a tube of 50 ml were placed 10 ml mouthwash (Listerine Cool Mint, Johnson \& Johnson, 21.6% alcohol). Patients were instructed to rinse their mouth vigorously with this quantity of mouthwash during 30 s, then spit it into the tube. Once collected, the samples were stored at room temperature (20°C - 24°C). The 60 samples were divided into 3 groups (n=20), and the extraction of DNA was performed at distinct times: group A at 10 days, group B at 20 days and group C at 30 days.
2.3. DNA extraction To separate the mouthwash, the tube was centrifuged during 10 min at 10750x g. The supernatant was poured out and the cellular pellet washed with 1 ml of PBS, resuspended in the vortex for 30 s, and transferred to a new 2 ml tube. It was then centrifuged for 5 min at 2000x g, the supernatant poured out, and the pellet washed with 1.5 ml of PBS and resuspended in the vortex for 30 s. To this solution was added a 1 ml solution of lysis of nucleated cells (Wizard® Genomic DNA Purification Kit) before being shaken for 20 s, followed by incubation at 37 °C for 10 min. After adding 300 µl of protein precipitator solution (Wizard® Genomic DNA Purification Kit), the mixture was placed on ice for 5 min and then centrifuged at 15000x g for 3 min. The supernatant was put in a 1.5 ml tube containing 600 µL cold Isopropanol and homogenized gently, then centrifuged at 15000x for 3 min. The supernatant was poured out and 600 µL of 70% ethanol were added to a fresh preparation, which was centrifuged at 15000x g for 3 min. The supernatant was poured out and the tube was completely dried at room temperature. Finally, 100 µL rehydration solution (Wizard® Genomic DNA Purification Kit) was added and the mixture was incubated at 64 °C for 1 h before storing the samples at -20 °C to await further processing.
2.4. DNA evaluation Evaluation of the concentration and purity of DNA was determined by spectrophotometry with an ACT-GENE ASP-3700 spectrometer. The concentration of DNA was evaluated at 260 nm, while purity was estimated with the ratios of 260/203 and 260/280. The integrity of genomic DNA was assessed in a 0.8% agarose gel in 1% TBE (89 mM Tris Borate, 89 mM boric acid, 2 mM EDTA) by electrophoresis, and then the DNA was visualized with Gel-Red and read under UV light. DNA extracted from blood samples was used as the positive control.
2.5. PCR The PCR reaction was carried out in an Eppendorf Mastercycler® Personal apparatus with the HotStarTaq ® Master Mix Qiagen kit (No. de Cat 203445), following the manufacturer's instructions. To verify the quality and species (human) of the DNA extracted, primers were designed for the rs679620 polymorphism (forward 5´- ggg gCT TAA ggC ACA TgA gT-3; reverse 5´- ACT TCg ggA TgC CAg gAA Ag - 3´; Tm: 56°C, 40 cycles) that amplified a product of 485 bp. The final PCR product was evaluated with a 2% agarose gel. DNA extracted from blood samples was used as a positive control.
2.6. Sequencing To further verify the quality and species of the DNA obtained, the product resulting from PCR was sequenced with an Applied Biosystems 3130 sequencer and the BigDye® Terminator v3.1 Cycle Sequencing kit, following the manufacturer's instructions. Data were analyzed with Geneious version 7.1.3 software [23], using the NC_000011.10 sequence as the reference.
Study design
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group A | – | Device: saliva samples obtained with mouthwashEach patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group A at 10 days |
| Group B | – | Device: saliva samples obtained with mouthwashEach patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group B at 20 days |
| Group C | – | Device: saliva samples obtained with mouthwashEach patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group C at 30 days |
Who may qualify
- Ages
- 35 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- patients diagnosed with severe chronic periodontitis
Key inclusion criteria (2 listed)
- patients diagnosed with severe chronic periodontitis
- who signed the appropriate form allowing for the collection of saliva samples and the extraction of genomic DNA
Key exclusion criteria (2 listed)
- NO diagnosed with severe chronic periodontitis
- NO signed the appropriate form allowing for the collection of saliva samples and the extraction of genomic DNA
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| saliva samples obtained with mouthwashsaliva samples obtained with mouthwash | Device | Group A, Group B, Group C |
Primary outcome
DNA
Time frame: 10 days [group A], 20 days [group B], 30 days [group C]
high quality genomic DNA from saliva samples obtained with mouthwash.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2015.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Beatriz Buentello Volante, Doctorate principal investigator
Instituto de Oftalmología "Conde de Valenciana".
María Esther Ocharán Hernández, Doctorate principal investigator
Escuela Superior de Medicina, Instituto Politécnico Nacional
Claudia Camelia Claudia Camelia Calzada Mendoza, Doctorate principal investigator
Escuela Superior de Medicina, Instituto Politécnico Nacional
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Periodontal Disease "Unrecognized Condition", run by Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Aug 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Ángel Chávez Mendoza, PhD student (57296300 ext. 6280, angelchm77@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DNA (time frame: 10 days [group A], 20 days [group B], 30 days [group C]). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2015.